<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0204870.ref007">
 <label>7</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Ansell</surname>
   <given-names>SM</given-names>
  </name>, 
  <name>
   <surname>Lesokhin</surname>
   <given-names>AM</given-names>
  </name>, 
  <name>
   <surname>Borrello</surname>
   <given-names>I</given-names>
  </name>, 
  <name>
   <surname>Halwani</surname>
   <given-names>A</given-names>
  </name>, 
  <name>
   <surname>Scott</surname>
   <given-names>EC</given-names>
  </name>, 
  <name>
   <surname>Gutierrez</surname>
   <given-names>M</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma</article-title>. 
  <source>The New England journal of medicine</source>. 
  <year>2015</year>;
  <volume>372</volume>(
  <issue>4</issue>):
  <fpage>311</fpage>â€“
  <lpage>9</lpage>. 
  <pub-id pub-id-type="doi">10.1056/NEJMoa1411087</pub-id> ; PubMed Central PMCID: PMC4348009.
  <?supplied-pmid 25482239?>
  <pub-id pub-id-type="pmid">25482239</pub-id>
 </mixed-citation>
</ref>
